BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 11473532)

  • 41. Prolactin and reproductive medicine.
    Davis JR
    Curr Opin Obstet Gynecol; 2004 Aug; 16(4):331-7. PubMed ID: 15232488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review.
    Weil C
    Curr Med Res Opin; 1986; 10(3):172-95. PubMed ID: 3525009
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prolactin.
    Thorner MO
    Clin Endocrinol Metab; 1977 Mar; 6(1):201-22. PubMed ID: 408065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic effects of prolactin.
    Pirchio R; Graziadio C; Colao A; Pivonello R; Auriemma RS
    Front Endocrinol (Lausanne); 2022; 13():1015520. PubMed ID: 36237192
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine): Unveiling the strategy for lactation inhibition - A systematic review of clinical trials.
    Shrateh ON; Kumar KA; Jawed A; Shuja MH; Shamsi HUR; Naasan M
    J Gynecol Obstet Hum Reprod; 2024 Jun; 53(6):102783. PubMed ID: 38554942
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bromocriptine therapy: Review of mechanism of action, safety and tolerability.
    Naz F; Malik A; Riaz M; Mahmood Q; Mehmood MH; Rasool G; Mahmood Z; Abbas M
    Clin Exp Pharmacol Physiol; 2022 Aug; 49(8):903-922. PubMed ID: 35635035
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectivity of Bromocriptine Administration Towards Prolactin Positive Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Literature Review.
    Permana MY; Sarwanti S; Fauziah S
    Acta Med Indones; 2023 Oct; 55(4):465-474. PubMed ID: 38213041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions.
    Chien HY; Chen SM; Li WC
    Front Clin Diabetes Healthc; 2023; 4():935872. PubMed ID: 36993818
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
    Defronzo RA
    Diabetes Care; 2011 Apr; 34(4):789-94. PubMed ID: 21447659
    [No Abstract]   [Full Text] [Related]  

  • 50. Cabergoline-induced manic episode: case report.
    Yüksel RN; Elyas Kaya Z; Dilbaz N; Cingi Yirün M
    Ther Adv Psychopharmacol; 2016 Jun; 6(3):229-31. PubMed ID: 27354910
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus.
    Siamashvili M; Davis S
    Expert Opin Pharmacother; 2021 Feb; 22(2):241-247. PubMed ID: 33030357
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bromocriptine: does this drug of Parkinson's disease have a role in managing cardiovascular diseases?
    Kutikuppala LVS; Sharma S; Chavan M; Rangari G; Misra AK; Innamuri SR; Vijayakumar T; Varshitha G
    Ann Med Surg (Lond); 2024 Feb; 86(2):926-929. PubMed ID: 38333315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of dopamine agonists to target angiogenesis in women with endometriosis.
    Pellicer N; Galliano D; Herraiz S; Bagger YZ; Arce JC; Pellicer A
    Hum Reprod; 2021 Mar; 36(4):850-858. PubMed ID: 33355352
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of dopamine d2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemia/anovulation model in rats.
    Moro M; Inada Y; Miyata H; Komatsu H; Kojima M; Tsujii H
    Clin Exp Pharmacol Physiol; 2001 Aug; 28(8):651-8. PubMed ID: 11473532
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
    Rains CP; Bryson HM; Fitton A
    Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hyperprolactinaemia and pituitary adenomas in adolescence.
    Dissaneevate P; Warne GL
    J Pediatr Endocrinol Metab; 1998; 11(4):531-41. PubMed ID: 9777574
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cabergoline: a new drug for the treatment of hyperprolactinaemia.
    Ferrari C; Piscitelli G; Crosignani PG
    Hum Reprod; 1995 Jul; 10(7):1647-52. PubMed ID: 8582955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 3.